

On page 48, third line from bottom, change
"octahydrocyclo-penta" to --octahydrocyclopenta--.

On line 2 of the abstract, change "inhibititory" to --
inhibitory--.

In the Claims:

In claim 26, before "effective", insert
--antihypertensive--.

REMARKS

Most of the above amendments to the specification correct obvious errors in spelling, capitalization or punctuation. The amendment to page 18 corrects an obvious error: since the first part of the sentence refers to "ester forms", R^6 cannot be "OH". Additional support for this correction may be found in Example 2, Methods III, IV and V, and Example 5, Methods II, III and IV, wherein the starting materials are ethyl esters, i.e. R^6 is $-OCH_2CH_3$. Those amendments to the examples wherein 1:1 ratios of solvents are added (i.e. page 23 and 36) are obvious changes, since those skilled in the art would recognize that where no numerical ratio is indicated, a 1:1 ratio is assumed. On page 34, the addition of the hydrochloride salt to the title of the example corrects an obvious omission, since the HCl salt is the product of Method I, Step E. On page 42, the change in the names of the compounds from "endo" to "exo" correct obvious errors, since the "endo" analogs were previously named on page 40, lines 22 - 26 and page 41, lines 1-2. None of the amendments constitute new matter. The amendment to claim 26 is discussed below.

Applicants respectfully request that the rejection of claims 1-30 be reconsidered and all claims be allowed.